Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $11.00 by Analysts at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) had its price target cut by equities research analysts at HC Wainwright from $12.00 to $11.00 in a research report issued on Monday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 168.29% from the company's previous close.

Other analysts also recently issued research reports about the company. Bank of America downgraded Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective for the company. in a research report on Tuesday, April 22nd. Morgan Stanley lowered their price objective on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research report on Wednesday, March 5th. Oppenheimer lowered their price objective on Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating for the company in a research report on Wednesday, May 14th. Wedbush reiterated an "outperform" rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Finally, Truist Financial lowered their price objective on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Two analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, Y-mAbs Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $16.60.

Y-mAbs Therapeutics Price Performance

NASDAQ:YMAB opened at $4.10 on Monday. The business has a 50 day moving average of $4.47 and a 200 day moving average of $7.00. The company has a market capitalization of $185.66 million, a price-to-earnings ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $20.90 million during the quarter, compared to the consensus estimate of $19.97 million. As a group, sell-side analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the sale, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. This represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 22.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Acorn Capital Advisors LLC grew its stake in Y-mAbs Therapeutics by 13.1% in the first quarter. Acorn Capital Advisors LLC now owns 3,235,387 shares of the company's stock worth $14,333,000 after purchasing an additional 373,562 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Y-mAbs Therapeutics by 58.7% in the first quarter. Jacobs Levy Equity Management Inc. now owns 237,511 shares of the company's stock worth $1,052,000 after acquiring an additional 87,830 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of Y-mAbs Therapeutics by 869.3% in the first quarter. AQR Capital Management LLC now owns 164,788 shares of the company's stock worth $730,000 after acquiring an additional 147,788 shares during the last quarter. Cubist Systematic Strategies LLC grew its stake in shares of Y-mAbs Therapeutics by 223.9% in the first quarter. Cubist Systematic Strategies LLC now owns 155,522 shares of the company's stock worth $689,000 after acquiring an additional 107,511 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in shares of Y-mAbs Therapeutics in the first quarter worth $581,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.